This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Respreeza
  • /
  • Extension Study of Zemaira� i.v. Administration in...
Clinical trial

Extension Study of Zemaira� i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Read time: 1 mins
Last updated:1st Apr 2008

This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® i.v. administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The long-term verification of a disease-modifying benefit of Zemaira® on the progression of emphysema will be assessed by volume-adjusted lung density, measured yearly by computed tomography (CT).

Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency Who Completed Clinical Study CE1226_4001
Enrollment: 140
Study Start Date: April 2008
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)

Arm:
- Experimental: Zemaira

Category Value
Study start date 2008-04-01

View full details